Pancreatic Cancer Research

ResearcherBC Cancer AgencyActive in the last 2 years

Daniel John Renouf

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7597-6089; OpenAlex author ID A5001731680, A5068093557, A5160269823. Sources: OpenAlex.

Their work

Papers
56 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
2
Collaborators
151
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 4 papers · 2016: 1 paper · 2017: 4 papers · 2018: 2 papers · 2019: 5 papers · 2020: 5 papers · 2021: 8 papers · 2022: 4 papers · 2023: 3 papers · 2024: 5 papers · 2025: 6 papers · 2026: 6 papers

Papers 50 of 56

  1. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  2. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-26-0793↗
  3. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  4. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  5. Endogenous insulin mediates dynamic coordination between pancreatic cancer and systemic metabolism Co-author DOI 10.64898/2026.08.26.745597↗
  6. Parent-of-Origin-Aware Genomic Analysis to Enhance Cascade Testing in Pancreatic Cancer: A Population-Based Study Co-author DOI 10.64898/2026.10.30.26366356↗
  7. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  8. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  9. KRAS-induced STN1 (OBFC1) promotes proper CTC1-STN1-TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic… Co-author DOI 10.1093/nar/gkaf983↗
  10. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  11. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  12. New-onset diabetes as an emerging risk group for early detection of pancreatic cancer: current evidence, clinical challenge, and future directions. Co-author DOI 10.3389/fgstr.2025.1645459↗
  13. A Deep Learning Approach for the Identification of the Molecular Subtypes of Pancreatic Ductal Adenocarcinoma Based on Whole Slide Pathology Images. Co-author DOI 10.1016/j.ajpath.2024.08.006↗
  14. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  15. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Co-author DOI 10.1126/sciadv.adj3551↗
  16. Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles. Co-author DOI 10.1186/s40170-024-00357-z↗
  17. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  18. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma. First author DOI 10.1177/17588359231157651↗
  19. Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1242/jcs.260644↗
  20. Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fgene.2023.1282824↗
  21. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  22. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  23. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Last author DOI 10.1038/s41467-022-33718-7↗
  24. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  25. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3695↗
  26. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33304↗
  27. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  28. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  29. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Last author DOI 10.1158/1078-0432.ccr-20-1042↗
  30. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  31. Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. Co-author DOI 10.1177/11772719211049852↗
  32. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. Co-author DOI 10.21037/jgo-20-422↗
  33. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Co-author DOI 10.1002/cam4.2973↗
  34. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. Co-author DOI 10.1016/j.xcrm.2020.100131↗
  35. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  36. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  37. Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1543↗
  38. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.1588↗
  39. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Co-author DOI 10.1053/j.gastro.2019.05.004↗
  40. Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000500↗
  41. Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Co-author DOI 10.1101/mcs.a003681↗
  42. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-19-0191↗
  43. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. Co-author DOI 10.1186/s13053-018-0088-y↗
  44. Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorour… Last author DOI 10.1200/po.18.00057↗
  45. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated w… Co-author DOI 10.1002/cjp2.75↗
  46. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Co-author DOI 10.1097/coc.0000000000000193↗
  47. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospect… Co-author DOI 10.1097/coc.0000000000000205↗
  48. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-017-3634-5↗
  49. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. Co-author DOI 10.1007/s00280-016-3102-y↗
  50. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Co-author DOI 10.1002/cam4.459↗

Closest collaborators

The 25 strongest of 151 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David F. Schaeffer · 39 shared papers, 2015–2026 · strength 4.92
  2. Joanna M. Karasinska · 26 shared papers, 2017–2026 · strength 3.38
  3. James Thomas Topham · 21 shared papers, 2019–2026 · strength 2.91
  4. Jennifer Jane Knox · 16 shared papers, 2019–2026 · strength 1.97
  5. Steve Gallinger · 16 shared papers, 2015–2026 · strength 1.84
  6. Steve E. Kalloger · 18 shared papers, 2015–2025 · strength 1.78
  7. Faiyaz Notta · 13 shared papers, 2020–2026 · strength 1.58
  8. Grainne Mary O'Kane · 13 shared papers, 2020–2025 · strength 1.54
  9. Sharlene Gill · 10 shared papers, 2012–2026 · strength 1.07
  10. Hui‐Li Wong · 11 shared papers, 2017–2022 · strength 0.95
  11. Erica S. Tsang · 7 shared papers, 2019–2025 · strength 0.89
  12. George Zogopoulos · 7 shared papers, 2020–2026 · strength 0.87
  13. Sandra Elisabeth Fischer · 7 shared papers, 2020–2025 · strength 0.83
  14. Robert C. Grant · 7 shared papers, 2020–2025 · strength 0.83
  15. Oliver F. Bathe · 6 shared papers, 2021–2025 · strength 0.80
  16. Thierry Conroy · 4 shared papers, 2024–2026 · strength 0.74
  17. Rémy Nicolle · 4 shared papers, 2024–2026 · strength 0.74
  18. James Biagi · 4 shared papers, 2024–2026 · strength 0.74
  19. Anthony Turpin · 4 shared papers, 2024–2026 · strength 0.74
  20. Jerome F. Cros · 4 shared papers, 2024–2026 · strength 0.74
  21. Aurélien Lambert · 4 shared papers, 2024–2026 · strength 0.74
  22. Pascal R. Hammel · 4 shared papers, 2024–2026 · strength 0.74
  23. Jean‐Baptiste Bachet · 4 shared papers, 2024–2026 · strength 0.74
  24. Nelson Dusetti · 4 shared papers, 2024–2026 · strength 0.74
  25. Rachel Anne Goodwin · 5 shared papers, 2021–2025 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.